Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Genotoxicity:
negative
Based on following OECD conform studies:
- In Vitro Mammalian Chromosomal Aberration Test (according to OECD 473)
- In Vitro Mammalian Cell Gene Mutation Tests using the Hprt and xprt genes (according to OECD 476)
- Bacterial Reverse Mutation Test (according to OECD 471)
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Metabolic activation:
- with and without
- Untreated negative controls:
- yes
- Remarks:
- Dimethyl sulphoxide
- Positive controls:
- yes
- Remarks:
- TA98, TA100, TA1535 and TA1537 strains of Salmonella typhimurium and WP2uvrA (pKM101) strain of Escherichia coli
- Details on test system and experimental conditions:
- TA98, TA100, TA1535 and TA1537 strains of Salmonella typhimurium and WP2uvrA (pKM101) strain of Escherichia coli
- Rationale for test conditions:
- The results of the study from both the initial and confirmatory mutation assay showed that, Licocare RBW 300 FL TP did not show any positive mutagenic increase at any of the tested doses either in the presence or in the absence of metabolic activation. Under identical test conditions, there was more than 3-fold increase in the mean numbers of revertant colonies in the positive controls, demonstrating the sensitivity of the assay procedure used.
- Evaluation criteria:
- Tester strain integrity
All Salmonella typhimurium tester strains and the Escherichia coli tester strain used in this assay must demonstrate their growth potential in the presence of histidine and tryptophan, respectively.
All Salmonella typhimurium tester strains must exhibit sensitivity to crystal violet and ultraviolet light to demonstrate the presence of rfa mutation and uvrB mutation, respectively.
Escherichia coli tester strain must exhibit sensitivity to ultraviolet light to demonstrate the presence of uvrA mutation.
Salmonella typhimurium strains TA98 and TA100 and Escherichia coli strain WP2uvrA (pKM101) must exhibit resistance to ampicillin to demonstrate the presence of the plasmid R-factor.
• The spontaneous reversion rates in the vehicle control must be in the range of in-house historical data.
• There must be at least three non-toxic dose levels.
• The top dose selected should demonstrate toxicity. In case of non-toxic test items, the top dose tested should be 5000 µg/plate.
• All tester strain culture titers must be in the range of 1-2 x 109 cells/mL to ensure that appropriate numbers of bacteria are used for plating.
• The positive control substances should produce a more than 3-fold increase in mutant colony frequencies when compared to the respective vehicle control plates. - Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- up to 5000 µg/plate
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- up to 5000 µg/plate
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- up to 5000 µg/plate
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- up to 5000 µg/plate
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- E. coli WP2 uvr A pKM 101
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- up to 5000 µg/plate
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- All criteria for a valid study were met as described in the study plan. It is concluded that the test item, Licocare RBW 300 FL TP, was not mutagenic in this bacterial reverse mutation test up to the OECD 471-recommended top dose of 5000 µg/plate under the conditions of testing employed.
- Executive summary:
The test item, Licocare RBW 300 FL TP was tested for its mutagenic potential in the bacterial reverse mutation assay. The study was conducted using TA98, TA100, TA1535 and TA1537 strains ofSalmonella typhimuriumand WP2uvrA (pKM101) strain ofEscherichia coliin three phases, a preliminary toxicity test, an initial mutation assay and a confirmatory mutation assay. The bacterial tester strains were exposed to the test item in the presence and absence of metabolic activation system (S9 fraction prepared from Aroclor 1254 induced rat liver).
Licocare RBW 300 FL TP formed a free flowing suspension in Dimethyl sulfoxide (DMSO) at 50 mg/mL.
In a preliminary toxicity test for the selection of test doses for the mutation assay, the test itemdid not precipitate on the basal agar plates at any of the tested doses.The test item did not show toxicity to the tester strain TA100 at any of the tested doses as the intensity of the bacterial background lawn as well as the mean number of revertant colonies were comparable to the vehicle control plates. Based on these observations, the test item was tested up to the OECD 471-recommended top dose of 5000 µg/plate in the mutation assay.
In the mutation assay, the bacterial tester strains were exposed to Licocare RBW 300 FL TPin triplicate at 50, 158, 500, 1581 and 5000mg/plate. The initial mutation assay was conducted using the direct plate incorporation mode of exposure and the confirmatory mutation assay was conducted using the pre-incubation mode of exposure. The vehicle control (DMSO) and the appropriate positive controls were tested simultaneously. The mean and standard deviation of numbers of revertant colonies were calculated for each test dose and the controls for all the tester strains.
The results of the study from both the initial and confirmatory mutation assay showed that, Licocare RBW 300 FL TP did not show any positive mutagenic increase at any of the tested doses either in the presence or in the absence of metabolic activation. Under identical test conditions, there was more than 3-fold increase in the mean numbers of revertant colonies in the positive controls, demonstrating the sensitivity of the assay procedure used.
The study indicated that Licocare RBW 300 FL TP was not mutagenic in this Bacterial Reverse Mutation Assay up to the OECD 471-recommended top dose of 5000mg/plate, under the conditions of testing employed.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- In vitro Mammalian Cell Gene Mutation Tests using the Hprt and xprt genes
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 05 September 2019 to 14 January 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- adopted on 29th July 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- other: In vitro Mammalian Cell Gene Mutation Tests using the Hprt and xprt genes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source: Clariant Plastics and Coatings (Deutschland) GmbH - Target gene:
- Hprt locus of CHO AA8 cells
- Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: ATCC
MEDIA USED
- Type and identity of media including CO2 concentration if applicable: Alpha MEM
- Properly maintained: yes - Metabolic activation:
- with and without
- Metabolic activation system:
- S9 liver homogenate
- Test concentrations with justification for top dose:
- 2 mg/mL as no change in pH and no precipitation was observed at and upto 2 mg/mL
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle:As test item formed suspension in DMSO - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- benzo(a)pyrene
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
- Cell density at seeding (if applicable): 2×106 per flask (8×106 per group)
DURATION
- Exposure duration: 3 to 6 hours
NUMBER OF REPLICATIONS: 01
METHODS OF STAINING TECHNIQUE USED: Giemsa - Rationale for test conditions:
- NA
- Evaluation criteria:
- Acceptance of test is based on the following criteria:
• Concurrent vehicle control is considered acceptable for addition to the laboratory historical vehicle control database as described in OECD guidelines for testing of chemicals, No. 476.
• Concurrent positive controls should induce responses that are compatible with those generated in the historical positive control data base and produce a statistically significant increase compared with the concurrent negative/vehicle control.
• Two experimental conditions (i.e. with and without metabolic activation) were tested unless one resulted in positive results.
• Adequate number of cells and concentrations are analyzable (according to OECD guidelines for testing of chemicals, No. 476).
• Criteria for selection of top concentration are consistent with those described in OECD guidelines for testing of chemicals, No. 476. - Statistics:
- Data of mutant frequencies were analyzed for differences among vehicle control, treatment and positive control groups by performing power transformation procedure by Snee and Irr (1981) with which, the observed mutant frequency was transformed using the formula:
Y=〖(X+A)〗^B
Where,
Y = transformed mutant frequency
X = observed mutant frequency
[Where X=(No. of mutant colonies per replicate)/(ACE value)×100
and A, B = constants (viz. A = 1 and B = 0.15)]
Statistical analysis of the experimental data was carried out using SPSS Statistical package version 22.0.
The statistical significances are designated by the superscripts as given below:
* Statistically significant (p<0.05) change than the vehicle control group. - Key result
- Species / strain:
- Chinese hamster Ovary (CHO)
- Remarks:
- up to the highet dose tested ( 2 mg /ml)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: No
- Water solubility: Insoluble
- Precipitation: No
HISTORICAL CONTROL DATA (with ranges, means and standard deviation and confidence interval (e.g. 95%)
- Positive historical control data:
Positive Control- Benzo(a)pyrene and 4- Nitroquinoline N-oxide
With Metabolic Activation
(3 to 6 hours)
[Benzo(a)pyrene] Without Metabolic Activation
(3 to 6 hours)
[4 Nitroquinoline N-oxide]
Mean Data of Mutant Frequency/2x106 Cells 261.94 264.60
Standard
Deviation 27.28 18.52
Margin of Error 17.82 12.10
Upper bound 279.76 276.70
Lower bound 244.12 252.50
- solvent/vehicle historical control data:
Vehicle-DMSO
With Metabolic Activation
(3 to 6 hours) Without Metabolic Activation
(3 to 6 hours)
Mean Data of Mutant Frequency/2x106 Cells 24.51 25.43
Standard
Deviation 2.81 1.89
Margin of Error 1.95 1.31
Upper bound 26.46 26.74
Lower bound 22.56 24.12 - Conclusions:
- Based on the results obtained, the test item, LICOCARE RBW 300 FL TP is considered as non-mutagenic at and up to concentration of 2 mg/mL, both in presence and absence of metabolic activation under the tested laboratory conditions.
- Executive summary:
The test itemLICOCARE RBW 300 FL TPwas evaluated to identify gene mutations induced using genetic endpoints to measure mutation at hypoxanthine-guanine phosphoribosyl transferase (HPRT) using the gene mutation test in CHO AA8 cells.The test item formed suspension in dimethyl sulphoxide (DMSO) at 200 mg/mL. Precipitation test was conducted at 0.0625, 0.125, 0.25, 0.50, 1 and 2 mg/mL. Post 3 hours of incubation, no change in pH and no precipitation was observed at and upto 2 mg/mL. On the basis of the results, 2 mg/mL was selected as the highest concentration for the initial cytotoxicity test. Initial cytotoxicity test was conducted at the concentrations of 0.125, 0.25, 0.5, 1 and 2 mg/mL using DMSO as a vehicle in tetra plates/group in the presence and absence of metabolic activation (3 to 6 hours).The results of the initial cytotoxicity test indicated that the Relative Survival is greater than 10 to 20 % at and upto 2 mg/mL when compared with the respective vehicle control, both in the presence and absence of metabolic activation. Based on the initial cytotoxicity test results, 2 mg/mL was selected as highest concentration for gene mutation test. The gene mutation test was conducted at concentrations of 0.25, 0.5, 1 and 2 mg/mL using DMSO as a vehicle in four plates / group in the presence and absence of metabolic activation (3 to 6 hours). Benzo(a) pyrene and4 Nitroquinoline N-oxidewere used asPositive controlsfor the gene mutation test.Cytotoxicity was assessed by determining the Adjusted Cloning Efficiencies and Relative Survival in the test.There was no statistically significant increase in number of mutant frequencies at any of the concentrations tested when compared with the vehicle control.Positive controls resulted in mutant frequencies,which were statistically significant when compared with the vehicle control.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 August 2019 to 19 November 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- OECD 473
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- Adopted on 29 July 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
- Specific details on test material used for the study:
SOLUBILTY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Ambient (15 to 25°C)
- Solubility of the test substance in the solvent/vehicle: Test item formed a suspension in dimethyl sulphoxide at 200 mg/mL- Species / strain / cell type:
- lymphocytes:
- Remarks:
- Human blood
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: Human peripheral lymphocytes
- Suitability of cells: Healthy, young, non-smoking donors
- proliferation : 2% phytohaemagglutinin (PHA)
- Sex, age and number of blood donors if applicable: Human peripheral lymphocytes from the blood of healthy, young, non-smoking donors 30 and 29 years (male) of age with no known recent exposure to genotoxic chemicals or radiation were used.
- Whether whole blood or separated lymphocytes were used if applicable: Whole blood
- Methods for maintenance in cell culture if applicable: CO2 INCUBATOR
- Modal number of chromosomes:46±2
MEDIA USED
- Type and identity of media : RPMI-1640 Culture media
- Properly maintained: yes - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat liver S9 homogenate
- Test concentrations with justification for top dose:
- Test concentrations are 0.5, 1 and 2 mg/mL, as the Percent mitotic index (MI %) was not more than 45±5% at 2 mg/mL, same concentration was selected as highest concentration and the other concentrations selected were 0.5 and 1 mg/mL for the chromosomal aberration test
- Vehicle / solvent:
- Dimethyl sulphoxide
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Dimethyl sulphoxide
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 3 to 6 hours and 20 to 24 hours
- Fixation time (start of exposure up to fixation or harvest of cells): 3 to 6 hours and 20 to 24 hours
STAIN (for cytogenetic assays): Giemsa
NUMBER OF REPLICATIONS: 02
METHODS OF SLIDE PREPARATION AND STAINING TECHNIQUE USED: Pellets were mixed with 3 to 4 mL of freshly prepared warm 0.56% Potassium chloride. Cell suspension was incubated for 10 minutes at room temperature and later it was centrifuged at 1800 rpm for 10 minutes. Supernatant was discarded and cell pellet was mixed with 3 mL of freshly prepared cold acetic acid:methanol fixative (1:3). Cell suspension was incubated for 10 minutes at room temperature and later suspension was centrifuged at 2200 rpm for 10 minutes. The procedure was repeated twice by adding 3 of cold acetic acid: methanol fixative (1:3).
Clean slides were stored in a beaker with distilled water and kept in the refrigerator for at least 1 hour before use. The cell suspension was mixed using a pipette and few drops of the suspension were aspirated and dropped onto the chilled slide pre labeled with study number, with (+S9) or without metabolic activation (-S9), treatment/group and slide number. The slides were air dried.
Minimum of 3 slides were prepared for each treatment replicate. Slides were stained using 5% Giemsa stain for 15 minutes
NUMBER OF CELLS EVALUATED: 500 cells (Initial cytotoxicity)
NUMBER OF METAPHASE SPREADS ANALYSED PER DOSE (if in vitro cytogenicity study in mammalian cells): 300 Metaphase per cultrue
DETERMINATION OF CYTOTOXICITY
- Method: Mitotic index - Rationale for test conditions:
- Not applicable
- Evaluation criteria:
- Considered acceptable for addition to the laboratory historical negative control database.
Adequate number of cells (at least 300 well spread metaphases per concentration) and concentrations (at least three analyzable concentrations) should be analyzed. - Statistics:
- Yes
- Key result
- Species / strain:
- lymphocytes:
- Remarks:
- human peripheral lymphocytes from blood
- Metabolic activation:
- with
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Remarks:
- up to 2 mg/mL
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks:
- 10 µg/mL of cyclophosphamide monohydrate in the presence of metabolic activation induced 10 % aberrant cells.
- Key result
- Species / strain:
- lymphocytes:
- Remarks:
- uman peripheral lymphocytes from blood
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Remarks:
- up to 2 mg/ mL
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: No change in pH observed in any of the concentrations tested up to 2 mg/mL
- Water solubility: No
- Precipitation: Moderate and mild precipitation was observed at 2 and 1 mg/mL respectively and no precipitation observed in any other concentrations.
RANGE-FINDING/SCREENING STUDIES:
HISTORICAL CONTROL DATA (with ranges, means and standard deviation
- Positive historical control data:
With S9 - cyclophosphamide monohydrate
(3 to 6 hours) Without S9 - Mitomycin C (3 to 6 hours) Without S9 - Mitomycin C (20 to 24 hours)
Average (% of Aberrated cells) 9.88 9.90 10.42
Standard Deviation 1.12 1.26 1.89
Sample size 16.00 16.00 16.00
Margin of error 0.55 0.62 0.93
Upper bound 10.43 10.52 11.34
Lower bound 9.33 9.28 9.49
95% Confidence level 1.96 1.96 1.96
Max 12.00 13.35 16.00
Min 8.67 8.67 8.67
- Negative (solvent/vehicle) historical control data:
With S9
(3-6 hours) Without S9 (3-6 hours) Without S9 (20-24 hours)
Average (% of Aberrated cells) 0.76 0.90 0.81
Standard Deviation 0.24 0.24 0.29
Sample size 12.00 12.00 12.00
Margin of error 0.14 0.14 0.16
Upper bound 0.90 1.04 0.97
Lower bound 0.62 0.76 0.65
95% Confidence level 1.96 1.96 1.96
Max 1.00 1.33 1.30
Min 0.35 0.67 0.34
ADDITIONAL INFORMATION ON CYTOTOXICITY:
- Measurement of cytotoxicity used: The percentage reduction in Mitotic Index
- Other observations when applicable: Metaphase counting - Remarks on result:
- other: Non genotoxic
- Remarks:
- NON-CLASTOGENIC
- Conclusions:
- Summary:
Test item formed suspension in DMSO. Precipitation test was conducted at 0.03125, 0.0625, 0.125, 0.25, 0.5, 1 and 2 mg/mL. Post 23 hours and 28 minutes of incubation, moderate and mild precipitation was observed at 2 and 1 mg/mL respectively and no precipitation observed in any other concentrations. No change in pH observed in any of the concentrations tested up to 2 mg/mL. Hence 2 mg/mL was selected as highest concentration for testing in the initial cytotoxicity test. The other concentrations tested were 0.125, 0.25, 0.5 and 1 mg/mL of test item.
The percentage reduction in Mitotic Index was in the range of 0.75 to 11.85 upto 2 mg/mL. As the percentage reduction in MI was not more than 45±5% at 2 mg/mL, same was selected as the highest concentration for the chromosomal aberration test. Other concentrations tested were 0.5 and 1 mg/mL.
In the chromosomal aberration test, the cells were treated with Licocare RBW 300 FL TP at the concentrations of 0.5, 1 and 2 mg/mL using DMSO as the vehicle. The treatment was carried out in duplicates for the short term period (3 to 6 hours) both in the presence and absence of metabolic activation and for the long term period (20 to 24 hours) in the absence of metabolic activation. Cyclophosphamide Monohydrate (+S9 for short term) at the concentration of 10 µg/mL and Mytomycin-C at the concentration of 0.05 µg/mL (-S9 both for short term and long term) were used as positive controls.
The treated cells were harvested at about 1.5 normal cell cycle length after treatment. During harvesting of cultures, the cells were treated with a metaphase-arresting substance (colchicine), harvested, stained and metaphase cells were analysed microscopically for the structural chromosomal aberrations.
The observed mean percent aberrated cells at 0.5, 1 and 2 mg/mL in the presence of metabolic activation (short term treatment 3 to 6 hours) were 1.33, 1.33, and 1.00 respectively. Similarly, the observed mean percent aberrated cells at 0.5, 1 and 2 mg/mL in the absence of metabolic activation (short term treatment 3 to 6 hours) were 1.00, 1.67 and 1.34 respectively.
The observed mean percent aberrated cells at 0.5, 1 and 2 mg/mL in the absence of metabolic activation, long term (20 to 24 hours) were 1.00, 1.67 and 1.67 respectively.
The cultures treated with positive controls for the short-term period (3 to 6 hours) both in the presence and absence of metabolic activation, and for the long-term period (20 to 24 hours) in the absence of metabolic activation induced were 10.00%, 10.34% and 11.00% of aberrated cells respectively, which was statistically significant compared with the respective vehicle control. This demonstrated sensitivity of the test system towards positive controls and confirmed that the test conditions were adequate.
The concurrent vehicle control values were within the 95% control limits of the distribution of the laboratory’s historical vehicle control database.
There was no statistically significant increase in the number of aberrated cells when compared with vehicle control at any of the concentration levels tested.
Conclusion :
Based on the results obtained, the test item, Licocare RBW 300 FL TP is considered as non-clastogenic up to the concentration of 2 mg/mL both in the presence and absence of metabolic activation under the presented test conditions. - Executive summary:
The test item,Licocare RBW 300 FL TPobtained fromClariant Plastics and Coatings (Deutschland) GMBH was evaluated for chromosomal aberrations in human lymphocytes, as per the OECD guideline for the testing of chemicals, No. 473 “In vitroMammalian Chromosomal AberrationTest” adopted on 29thJuly 2016.
Based on the results obtained, the test item,Licocare RBW 300 FL TP isconsidered as non-clastogenic up to the concentration of 2 mg/mL both in the presence and absence of metabolic activation under the presented test conditions
Referenceopen allclose all
Table 1. Results of Preliminary Toxicity Test
Treatment (mg/plate) |
TA 100 revertant colonies/plate* |
||||||||||||
Presence of Metabolic Activation |
Absence of Metabolic Activation |
||||||||||||
Mean |
Background lawn Intensity** |
Precipitation** |
Mean |
Background lawn Intensity** |
Precipitation** |
||||||||
DMSO |
112 |
4+ |
NPO |
113 |
4+ |
NPO |
|||||||
50 |
111 |
4+ |
NPO |
107 |
4+ |
NPO |
|||||||
100 |
112 |
4+ |
NPO |
107 |
4+ |
NPO |
|||||||
200 |
109 |
4+ |
NPO |
108 |
4+ |
NPO |
|||||||
400 |
106 |
4+ |
NPO |
107 |
4+ |
NPO |
|||||||
800 |
107 |
4+ |
NPO |
105 |
4+ |
NPO |
|||||||
1600 |
108 |
4+ |
NPO |
107 |
4+ |
NPO |
|||||||
3200 |
108 |
4+ |
NPO |
107 |
4+ |
NPO |
|||||||
5000 |
106 |
4+ |
NPO |
107 |
4+ |
NPO |
*: Mean of two replicates **: Refer Appendix 7
Table 2. Viable Counts of the Overnight Culture of the Tester Strains
Tester Strains |
Viable Counts (x 109CFU/mL*) |
||||
Initial Mutation Assay |
Confirmatory Mutation Assay |
||||
TA98 |
1.54 |
1.56 |
|||
TA100 |
1.58 |
1.57 |
|||
TA1535 |
1.55 |
1.56 |
|||
TA1537 |
1.56 |
1.58 |
|||
WP2uvrA (pKM101) |
1.63 |
1.62 |
* Required Cell count: 1-2x109Colony Forming Units (CFU)/mL
TALBE 3. Summary Results of Initial Mutation Assay in the Presence of Metabolic Activation
Treatment (µg/plate) |
No. of revertants/platea |
||||||||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2uvrA(pKM101) |
|||||||||||
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
|
DMSO |
26 |
2 |
NA |
108 |
3 |
NA |
16 |
3 |
NA |
13 |
3 |
NA |
148 |
3 |
NA |
50 |
25 |
2 |
0.96 |
108 |
2 |
1.00 |
16 |
2 |
1.02 |
13 |
2 |
1.00 |
146 |
3 |
0.99 |
158 |
26 |
2 |
1.00 |
105 |
2 |
0.97 |
15 |
2 |
0.94 |
13 |
2 |
0.95 |
147 |
4 |
0.99 |
500 |
26 |
2 |
1.01 |
105 |
3 |
0.98 |
14 |
2 |
0.88 |
12 |
1 |
0.90 |
146 |
4 |
0.99 |
1581 |
25 |
2 |
0.95 |
105 |
3 |
0.97 |
13 |
3 |
0.83 |
12 |
2 |
0.88 |
147 |
4 |
0.99 |
5000 |
25 |
3 |
0.95 |
106 |
3 |
0.98 |
13 |
2 |
0.83 |
11 |
1 |
0.83 |
146 |
2 |
0.99 |
Positive controls |
364c |
8c |
14.01c |
765c |
15c |
7.08c |
163c |
6c |
10.21c |
164c |
9c |
12.33c |
576d |
8d |
3.89d |
aValues are means of three replicates calculated from Appendix 3 and are rounded off to the nearest whole number bRatio of treated/vehicle control (mean revertants per plate). The presentation was made using the mean values with decimals before rounding off to the nearest whole number. Hence, some of the values may not match if calculated using the rounded-off mean values of this summary table. cTA98, TA100, TA1535, TA1537: 2-Aminoanthracene (4 µg/plate) dWP2uvrA(pKM101): 2-Aminoanthracene (30 µg/plate) NA: Not applicable SD: Standard deviation |
Table 4. Summary Results of Initial Mutation Assay in the Absence of Metabolic Activation
Treatment (µg/plate) |
No. of revertants/platea |
||||||||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2uvrA(pKM101) |
|||||||||||
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
|
DMSO |
26 |
2 |
NA |
107 |
2 |
NA |
14 |
2 |
NA |
14 |
2 |
NA |
146 |
3 |
NA |
50 |
24 |
3 |
0.95 |
107 |
3 |
1.00 |
15 |
2 |
1.07 |
12 |
3 |
0.90 |
148 |
2 |
1.01 |
158 |
25 |
2 |
0.97 |
107 |
5 |
1.00 |
15 |
2 |
1.02 |
12 |
2 |
0.90 |
148 |
4 |
1.02 |
500 |
25 |
2 |
0.97 |
104 |
3 |
0.98 |
14 |
3 |
0.98 |
13 |
2 |
0.93 |
145 |
3 |
0.99 |
1581 |
25 |
3 |
0.97 |
106 |
4 |
0.99 |
14 |
3 |
0.95 |
13 |
3 |
0.93 |
146 |
3 |
1.00 |
5000 |
24 |
2 |
0.93 |
105 |
4 |
0.98 |
14 |
2 |
1.00 |
13 |
2 |
0.93 |
144 |
3 |
0.99 |
Positive controls |
273c |
9c |
10.65c |
562d |
7d |
5.26d |
152d |
10d |
10.63d |
163e |
12e |
11.92e |
566f |
14f |
3.89f |
aValues are means of three replicates calculated from Appendix 4 and are rounded off to the nearest whole number bRatio of treated/vehicle control (mean revertants per plate). The presentation was made using the mean values with decimals before rounding off to the nearest whole number. Hence, some of the values may not match if calculated using the rounded-off mean values of this summary table. cTA98: 2-Nitrofluorene (2 µg/plate), dTA100, TA1535: Sodium azide (1 µg/plate), eTA1537: 9-Aminoacridine (50 µg/plate), fWP2uvrA(pKM101): 4-Nitroquinoline-1-oxide (4 µg/plate) NA: Not applicable SD: Standard deviation |
Table 5. Summary Results of Confirmatory Mutation Assayin the Presence of Metabolic Activation
Treatment [µg/plate] |
No. of revertants/platea |
||||||||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2uvrA (pKM101) |
|||||||||||
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
|
DMSO |
26 |
3 |
NA |
112 |
3 |
NA |
17 |
2 |
NA |
15 |
3 |
NA |
147 |
5 |
NA |
50 |
26 |
2 |
0.99 |
107 |
4 |
0.96 |
16 |
3 |
0.98 |
13 |
2 |
0.86 |
148 |
4 |
1.00 |
158 |
25 |
2 |
0.95 |
109 |
3 |
0.97 |
16 |
3 |
0.94 |
14 |
2 |
0.95 |
148 |
3 |
1.01 |
500 |
25 |
3 |
0.95 |
104 |
4 |
0.93 |
16 |
2 |
0.94 |
13 |
2 |
0.89 |
146 |
3 |
1.00 |
1581 |
26 |
2 |
1.00 |
107 |
3 |
0.96 |
15 |
3 |
0.88 |
13 |
2 |
0.86 |
146 |
4 |
1.00 |
5000 |
25 |
3 |
0.94 |
108 |
3 |
0.96 |
14 |
3 |
0.82 |
13 |
3 |
0.89 |
144 |
4 |
0.98 |
Positive controls |
372c |
15c |
14.11c |
766c |
22c |
6.86c |
155c |
9c |
9.32c |
161c |
13c |
11.00c |
568d |
18d |
3.87d |
aValues are means of three replicates calculated from Appendix 5 and are rounded off to the nearest whole number bRatio of treated/vehicle control (mean revertants per plate).The presentation was made using the mean values with decimals before rounding off to the nearest whole number. Hence, some of the values may not match if calculated using the rounded-off mean values of this summary table. cTA98, TA100, TA1535, TA1537: 2-Aminoanthracene (4 µg/plate) dWP2uvrA(pKM101): 2-Aminoanthracene (30 µg/plate) NA: Not applicable SD: Standard deviation |
Table 6. Summary Results of Confirmatory Mutation Assay in the Absence of Metabolic Activation
Treatment [µg/plate] |
No. of revertants/platea |
||||||||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2uvrA (pKM101) |
|||||||||||
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
Mean |
SD |
Ratiob |
|
DMSO |
27 |
2 |
NA |
108 |
2 |
NA |
16 |
2 |
NA |
14 |
3 |
NA |
148 |
3 |
NA |
50 |
25 |
2 |
0.95 |
107 |
4 |
0.99 |
15 |
2 |
0.92 |
12 |
2 |
0.85 |
147 |
3 |
0.99 |
158 |
27 |
2 |
1.00 |
106 |
3 |
0.98 |
15 |
1 |
0.90 |
12 |
1 |
0.85 |
146 |
4 |
0.99 |
500 |
25 |
3 |
0.94 |
108 |
3 |
1.00 |
16 |
3 |
1.00 |
11 |
2 |
0.78 |
146 |
4 |
0.99 |
1581 |
26 |
2 |
0.97 |
107 |
4 |
0.99 |
15 |
3 |
0.90 |
12 |
2 |
0.88 |
145 |
3 |
0.98 |
5000 |
25 |
2 |
0.94 |
103 |
3 |
0.96 |
14 |
2 |
0.88 |
12 |
2 |
0.90 |
145 |
4 |
0.98 |
Positive controls |
276c |
15c |
10.36c |
567d |
19d |
5.25d |
158d |
11d |
9.65d |
166e |
11e |
12.12e |
564f |
8f |
3.80f |
aValues are means of three replicates calculated from Appendix 6 and are rounded off to the nearest whole number bRatio of treated/vehicle control (mean revertants per plate). The presentation was made using the mean values with decimals before rounding off to the nearest whole number. Hence, some of the values may not match if calculated using the rounded-off mean values of this summary table. cTA98: 2-Nitrofluorene (2 µg/plate), dTA100, TA1535: Sodium azide (1 µg/plate) eTA1537: 9-Aminoacridine (50 µg/plate), fWP2uvrA(pKM101): 4-Nitroquinoline-1-oxide (4 µg/plate) NA: Not applicable SD: Standard deviation |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Link to relevant study records
- Endpoint:
- genetic toxicity in vivo, other
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 December 2019 to 14 April 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- 29th July 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian erythrocyte micronucleus test
- Species:
- mouse
- Strain:
- Swiss
- Remarks:
- Albino
- Details on species / strain selection:
- Mouse is one of the recommended species by regulatory agencies for conducting in vivo Micronucleus test among rodents
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: In-house
- Age at study initiation: 7 to 9 weeks
- Weight at study initiation: 18 to 23 g
- Assigned to test groups randomly: Through grouping and randomization
- Fasting period before study: NA
- Housing: Maximum of five animals of same sex and group were housed together in a standard polypropylene cage (L 280 × B 220 × H 140 mm) with stainless steel mesh top grill having facilities for holding pelleted feed and drinking water in water bottle fitted with stainless steel sipper tube. Sterilized paddy husk was used as a bedding material
- Diet (e.g. ad libitum): Altromin Maintenance Diet for rats and mice (manufactured by Altromin Spezialfutter GmbH & Co. KG) was provided ad libitum to the animals throughout the experimental period
- Water (e.g. ad libitum):Water was provided ad libitum throughout the acclimatization and experimental period. Deep bore-well water passed through reverse osmosis unit was provided in plastic water bottles with stainless steel sipper tubes
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.3 to 22.9°C
- Humidity (%): 44 to 65%
- Air changes (per hr): 12 to 15
- Photoperiod (hrs dark / hrs light): 12 hours dark and 12 hours light
IN-LIFE DATES: From: 26/12/2019 To: 05/03/2020 - Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: corn oil
- Justification for choice of solvent/vehicle: Corn oil is universally accepted vehicle for acute oral dosing
- Concentration of test material in vehicle: 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg body weight
- Lot no. (if required): A1712001 - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Required quantity of test item was weighed as per the dose. The weighed test item was transferred to a clean mortar and ground using pestle by adding a small quantity of vehicle to get a uniform suspension. The content was transferred to a measuring cylinder. Again, a small quantity of Corn oil was added to the mortar rinsed and transferred to the measuring cylinder. The rinsing procedure was repeated until the test item was transferred completely into the measuring cylinder. The final volume was made up with corn oil to get the desired concentration as per the dose requirement. Formulation of the test item was prepared freshly every day before dosing
- Duration of treatment / exposure:
- The test item was administered through oral route once a day for 2 consecutive days using gavage cannula.
- Frequency of treatment:
- once a day for 2 consecutive days
- Post exposure period:
- 18 to 24 hours
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Limit Study: 3 groups
10 (5 Males + 5 Females) - Control animals:
- yes, concurrent no treatment
- yes, concurrent vehicle
- Positive control(s):
- cyclophosphamide;
- Justification for choice of positive control(s): As per inhouse validation study
- Route of administration: Oral
- Doses / concentrations: 100 mg/kg body weight/10 mg/mL - Tissues and cell types examined:
- For each animal 500 erythrocytes (which include mature and immature erythrocytes) were scored to determine the Polychromatic Erythrocytes (PCE) and Normochromatic Erythrocytes (NCE) ratio, in order to determine PCE: total erythrocytes ratio.
For each animal, a minimum of 4000 Polychromatic Erythrocytes (PCEs) were scored for the incidence of micronucleated immature erythrocytes (MNPCEs) - Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: In pre study, none of the doses produced observable toxic effects (no depression of bone marrow proliferation or other evidence of cytotoxicity were observed up to 2000 mg/kg) and hence; 2000 mg/kg was selected as the limit dose for both the sexes in Limit study
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields): Post 18 to 24 hours (Day 3) of the second day treatment, all surviving animals were sacrificed by cervical dislocation, the femur was isolated from each animal for bone marrow collection
DETAILS OF SLIDE PREPARATION: Bone marrow cells were obtained by cut opening the epiphyses of femur bone immediately following sacrifice. The marrow was flushed out in to a centrifuge tube using the Fetal Bovine Serum (FBS). The femur bone marrow cells were centrifuged at about 2700 rpm for 10 minutes. Prior to smear preparation, the supernatant was discarded and the cell pellet is then resuspended in approximately 50 µL of Fetal Bovine Serum.
Minimum of three slides were prepared for pre study and main study per animal. Smears before staining was fixed by immersing the slides in methanol for approximately 5 to 6 minutes. The air dried slides were stained with May-Gruenwald and Giemsa stain for evaluation.
METHOD OF ANALYSIS:
OTHER: - Evaluation criteria:
- In the dose range finding study for each animal, minimum of 500 erythrocytes (which include mature and immature erythrocytes) were scored to determine the Polychromatic Erythrocytes (PCE) and Normochromatic Erythrocytes (NCE) ratio, in order to determine PCE: total erythrocytes ratio. This result was used to determine the cytotoxicity of the test item.
In the limit study, all the slides including those of positive and vehicle controls were coded before microscopic evaluation to avoid group bias during evaluation.
For each animal, a minimum of 500 erythrocytes (which included mature and immature erythrocytes) were scored from first slide of the animal to determine PCE: total erythrocytes ratio along with the incidence of micronucleus. The subsequent slides were scored only for the number of PCEs and incidence of micronucleated PCEs. For each animal, a minimum of 4000 Polychromatic Erythrocytes (PCEs) were scored for the incidence of micronucleated immature erythrocytes (MNPCEs) - Statistics:
- Body weight of both pre study and limit study was analyzed by SPSS, version No. 22 at a 95% level (p≤0.05) of significance. Inter group comparison of Body weight of Day 1, 2 and 3 were done. Slides from limit study were decoded after analysis; the number of PCE (Polychromatic erythrocytes), RBC (Red blood corpuscles), MNPCE (Micronucleated Polychromatic erythrocytes) and PCE/ total erythrocytes ratio (Polychromatic erythrocytes/ total erythrocytes) and frequency of MNPCE was calculated. The data of positive control and the treatment groups were compared with that of the vehicle control for the incidence of MNPCEs and the proportion of PCEs among total RBCs by SPSS at a 95% level (p≤0.05) of significance. All analysis and comparisons were evaluated at the 95% level of confidence (p<0.05).
Statistically significant changes obtained were designated by the superscripts in the summary table throughout the report as stated below:
*: Statistically significant (p<0.05) - Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- not valid
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range: Yes
- Solubility: Suspension in corn oil
- Clinical signs of toxicity in test animals: No clinical signs observed
- Evidence of cytotoxicity in tissue analyzed: No toxicity observed
- Harvest times: 18 to 24 hours of day 2 treatment
RESULTS OF DEFINITIVE STUDY
- Induction of micronuclei (for Micronucleus assay): Yes
- Ratio of PCE/NCE (for Micronucleus assay): Yes
- Appropriateness of dose levels and route: Yes
- Statistical evaluation: Yes - Conclusions:
- Based on the results obtained under the conditions employed during this experiment, it is concluded that the test item, Licocare RBW 300 FL TP is non-genotoxic at the limit dose of 2000 mg/kg.
- Executive summary:
Test item,Licocare RBW 300 FLwas evaluated in the MammalianErythrocyte Micronucleus Test.
This study was conducted to determine the genotoxic potential ofLicocare RBW 300 FL TP inthe micronucleus test using bone marrow cells of Swiss Albino mice. The pre study consisted of four groups, vehicle control, 500, 1000 and 2000 mg/kg.Licocare RBW 300 FL TPwasadministered at a dose volume of 10 mL/kg. In the pre study, each group of mice consisted of 3 males and 3 females. The main study consisted of 3 groups of mice and each group consisted of 5 males and 5 females. G1 group animals were administered with vehicle, G2 group animals were administered with cyclophosphamide monohydrate at 100 mg/kg and animals of G3 group were administered with a limit dose of 2000 mg/kg for two consecutive days by oral route using gavage cannula. Post 18 to 24 hours of last dosing, all mice were sacrificed by cervical dislocation and bone marrow cells were collected. The slides of bone marrow cells were stained with May-Gruenwald and Giemsa stain and observed for incidences of micronucleated polychromatic erythrocytes (MNPCE).
In pre study, no clinical signs,no body weight changes, no gross pathological findingsand no mortality were observed in any of the animals dosed withLicocare RBW 300 FL TPin any of the dose levels.
In pre study, there was statistical significant decrease in thePCE: total erythrocytesratio at 500, 1000 and 2000 mg/kg in females and in males at 2000 mg/kgwhen compared to vehicle control group. The reduction in PCE: total erythrocytes was well below 50% (3.92% in males and 9.80% in females) and the test item was therefore considered not to be cytotoxic to the bone marrow. In pre study, none of the doses produced observable toxic effects (no depression of bone marrow proliferation or other evidence of cytotoxicity) hence,2000 mg/kg was selected as the limit dose for both the sexes in main study.
In the main study, there was no clinical signs, no body weight changes, no gross pathological findings and no mortality were observed in any of the animals dosed with test item at 2000 mg/kg and also in positive control dosed animals. There was statistical significant decrease in proportions of PCE: total erythrocytes ratio in animals dosed at 2000 mg/kg of test item and also in positive control group in both the sexes when compared to vehicle control group. The average percentage of MNPCEs was 0.05 in both the sexes dosed with vehicle. There was no statistically significant increase in thepercentageof micronucleated PCEs (per 4000 PCEs scored) at 2000 mg/kg in comparison with vehicle control.
The positive control,cyclophosphamide monohydrate at 100 mg/kgexhibited statistically significant increase in the percentage of MNPCE when compared to vehicle control. Thisdemonstrated the sensitivity of the test system towards positive controls and confirmed that the test conditions were adequate.
Reference
INDIVIDUAL ANIMAL MICRONUCLEUS DATA - MAIN STUDY
Sex |
Group & Dose (mg/kg) |
Animal No. |
Total NCEs |
Total PCEs |
PCE: Total Erythrocytes Ratio |
Mean of PCE: Total Erythrocytes Ratio |
SD |
% Reduction Of PCE: Total Erythrocytes Ratio |
Total No. of PCE's Scored |
Total Number of MNPCEs |
% of MNPCEs |
Mean of % of MNPCEs |
Male |
G1 & 0 |
Mc5271 |
255 |
276 |
0.52 |
0.51 |
0.00 |
NA |
4010 |
2 |
0.05 |
0.05 |
Mc5272 |
254 |
266 |
0.51 |
4021 |
3 |
0.07 |
||||||
Mc5273 |
253 |
267 |
0.51 |
4151 |
2 |
0.05 |
||||||
Mc5274 |
256 |
266 |
0.51 |
4008 |
2 |
0.05 |
||||||
Mc5275 |
255 |
270 |
0.51 |
4215 |
1 |
0.02 |
||||||
G2 & 100 (CPA) |
Mc5276 |
274 |
234 |
0.46 |
0.47* |
0.01 |
7.84 |
4017 |
30 |
0.75 |
0.69* |
|
Mc5277 |
270 |
240 |
0.47 |
4032 |
26 |
0.64 |
||||||
Mc5278 |
280 |
245 |
0.47 |
4011 |
25 |
0.62 |
||||||
Mc5279 |
265 |
240 |
0.48 |
4017 |
30 |
0.75 |
||||||
Mc5280 |
280 |
246 |
0.47 |
4015 |
27 |
0.67 |
||||||
G3 & 2000 |
Mc5281 |
285 |
251 |
0.47 |
0.46* |
0.01 |
9.80 |
4121 |
4 |
0.10 |
0.07 |
|
Mc5282 |
270 |
231 |
0.46 |
4015 |
3 |
0.07 |
||||||
Mc5283 |
275 |
225 |
0.45 |
4012 |
2 |
0.05 |
||||||
Mc5284 |
286 |
244 |
0.46 |
4022 |
3 |
0.07 |
||||||
Mc5285 |
280 |
240 |
0.46 |
4125 |
3 |
0.07 |
SD: Standard deviation, CPA: Cyclophosphamide Monohydrate, *: Statistically significant
INDIVIDUAL ANIMAL MICRONUCLEUS DATA - MAIN STUDY
Sex |
Group & Dose (mg/kg) |
Animal No. |
Total NCEs |
Total PCEs |
PCE: Total erythrocytes ratio |
Mean of PCE: Total erythrocytes ratio |
SD |
% Reduction of PCE: Total erythrocytes ratio |
Total No. of PCE's scored |
Total Number of MNPCEs |
% of MNPCEs |
Mean of % of MNPCEs |
Female |
G1 & 0 |
Mc5286 |
260 |
266 |
0.51 |
0.50 |
0.01 |
NA |
4125 |
2 |
0.05 |
0.05 |
Mc5287 |
265 |
264 |
0.50 |
4085 |
1 |
0.02 |
||||||
Mc5288 |
255 |
258 |
0.50 |
4151 |
2 |
0.05 |
||||||
Mc5289 |
258 |
263 |
0.50 |
4063 |
3 |
0.07 |
||||||
Mc5290 |
265 |
258 |
0.49 |
4017 |
2 |
0.05 |
||||||
G2 & 100 (CPA) |
Mc5291 |
290 |
243 |
0.46 |
0.47* |
0.01 |
6.00 |
4021 |
25 |
0.62 |
0.65* |
|
Mc5292 |
287 |
259 |
0.47 |
4125 |
30 |
0.73 |
||||||
Mc5293 |
279 |
248 |
0.47 |
4063 |
27 |
0.66 |
||||||
Mc5294 |
280 |
266 |
0.49 |
4011 |
25 |
0.62 |
||||||
Mc5295 |
289 |
257 |
0.47 |
4032 |
25 |
0.62 |
||||||
G3 & 2000 |
Mc5296 |
270 |
230 |
0.46 |
0.45* |
0.01 |
10.00 |
4015 |
2 |
0.10 |
0.08 |
|
Mc5297 |
275 |
235 |
0.46 |
4101 |
3 |
0.07 |
||||||
Mc5298 |
278 |
223 |
0.45 |
4022 |
4 |
0.10 |
||||||
Mc5299 |
288 |
223 |
0.44 |
4021 |
3 |
0.07 |
||||||
Mc5300 |
287 |
248 |
0.46 |
4031 |
2 |
0.05 |
SD: Standard deviation, CPA: Cyclophosphamide Monohydrate, *: Statistically significant
Mode of Action Analysis / Human Relevance Framework
There is no evidence for species specific effects of the substance. Therefore, the results of the in vitro/in vivo data are regarded as relevant for humans.
Additional information
Due to the findings in the performed Ames test no classification for mutagenicity is recommended according to the criteria of Regulation (EC) No 1272/2008.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.